TY - JOUR
AU - Hézode, C
AB -  A number of new inhibitors of HCV lifecycle have reached early‐ to late‐stage clinical development. They include inhibitors of HCV replication such as nucleoside/nucleotide analogue inhibitors of HCV RdRp, non‐nucleoside inhibitors of HCV RdRp, NS5A inhibitors. Daclatasvir is a highly selective, first‐in‐class HCV NS5A replication complex inhibitor with picomolar potency, broad genotypic coverage in vitro . In recent phase 2 studies, the combination of daclatasvir with pegIFN/RBV for 24–48 weeks in previously untreated HCV genotype 1‐and 4‐infected patients achieved higher SVR rate than pegIFN/RBV alone and was well tolerated supporting the further development this combination in phase 3 studies including treatment‐naïve and ‐experienced patients. Nucleoside/nucleotide analogues act as natural polymerase substrates leading to termination of RNA chain elongation by inhibition of the active site of the HCV RdRp. These drugs have a pan‐genotype antiviral activity and they are considered to have a high genetic barrier to resistance. These inhibitors are currently investigated as part of triple combinations with pegIFN and RBV. In clinical trials, the most promising drug is sofosbuvir (nucleotide inhibitor). In a large open‐label, single‐group study of sofosbuvir, peg‐IFN and RBV for 12 weeks, naïve patients infected with predominantly HCV genotype 1 or 4 had a 
TI - O122: Peg‐IFN/RBV plus non‐protease inhibitors (NS5A, nucleotides)
JF - Journal of Viral Hepatitis
DO - 10.1111/jvh.12165_5
DA - 2013-09-01
UR - https://www.deepdyve.com/lp/wiley/o122-peg-ifn-rbv-plus-non-protease-inhibitors-ns5a-nucleotides-xqvcpQb2Kt
SP - 4
EP - 5
VL - 20
IS - 
DP - DeepDyve
ER -